In April 1990, Eric Davis was just two years old and diagnosed with aplastic anemia, a disease that would eventually require a bone marrow transplant for him to stay alive. When none of his family were matches, the family began raising the $100,000 required to find an unrelated donor. Finally in 2004, when his disease was no longer able to be controlled by the drugs the doctors prescribed, a donor was found in Germany. The transplant essentially cured Eric and he was able to thrive, later earning a degree in biology. He also found his way to New York City in 2011, working in a research lab at Memorial Sloan Kettering (MSK). When a position opened up to manage the Unrelated Donor Program at MSK, he jumped at the chance to be able to help patients like himself.
Technology in Cancer Research & Treatment is New and #OpenAccess
@SAGE_News ‘s Technology in Cancer Research & Treatment (TCRT) has recently been added to our collection. This is a broad-spectrum, open access, peer-reviewed publication whose aim is to provide researchers and clinicians with a platform to share and discuss developments in the prevention, diagnosis, treatment, and monitoring of cancer. TCRT welcomes original research (both basic and clinical studies), reviews, and commentaries. Authors interested in submitting a manuscript should consult the journal’s Submission Guidelines.
Technology in Cancer Research & Treatment may be accessed from our eJournal A-Z.
Combined Therapy for Glioblastoma, New Biomarker Blood Test and More…
Surfing the web, I uncovered these news items worth sharing
- Cancer researchers at Lund University in Sweden have teamed up with Robert Egnell at the Swedish Defence University to explore whether or not military strategy could be used as inspiration for cancer treatment.
- Results from a recent clinical trial shows that treating older patients who have malignant brain cancer with the chemotherapy drug temozolomide plus a short course of radiation therapy extended the life of patients with glioblastoma. The findings were published in the NEJM.
- A prospective clinical trial demonstrated that a that a blood test looking at specific biomarkers was able to detect recurrences of lung cancer an average of six months before conventional imaging methods found evidence of recurrence. The findings were recently presented at the 2017 Multidisciplinary Thoracic Cancers Symposium . From the list of abstracts, see #3.